The present invention relates to novel hydroxyethylene compounds having Asp2 (-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated -amyloid levels or -amyloid deposits, particularly Alzheimer's disease.